


What is claimed is:

1. A compound having Formula (I):



I

or a pharmaceutically acceptable salt thereof, wherein:

Cy¹ is selected from phenyl and 5-6 membered heteroaryl; wherein each 5-6 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, or 3 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of 5-6 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

R¹ is selected from Cl, C₁₋₂ alkyl, C₁₋₂ haloalkyl, hydroxymethyl, C₁₋₂ alkoxy, C₁₋₂ haloalkoxy and C₁₋₂ alkylamino; wherein optionally one or more H atoms of the C₁₋₂ alkyl, C₁₋₂ haloalkyl, hydroxymethyl, C₁₋₂ alkoxy, C₁₋₂ haloalkoxy and C₁₋₂ alkylamino are replaced by one or more D atoms;

each R² and R³ are independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₃ alkylene, 4-10 membered heterocycloalkyl-C₁₋₃ alkylene, C₆₋₁₀ aryl-C₁₋₃ alkylene, 5-10 membered heteroaryl-C₁₋₃ alkylene, halo, CN, NO₂, OR^{a2}, SR^{a2}, C(O)R^{b2}, C(O)NR^{c2}R^{d2}, C(O)OR^{a2}, OC(O)R^{b2}, OC(O)NR^{c2}R^{d2}, NR^{c2}R^{d2}, NR^{c2}C(O)R^{b2}, NR^{c2}C(O)OR^{a2}, NR^{c2}C(O)NR^{c2}R^{d2}, C(=NR^{e2})R^{b2}, C(=NOR^{a2})R^{b2}, C(=NR^{e2})NR^{c2}R^{d2}, NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}, NR^{c2}S(O)R^{b2}, NR^{c2}S(O)₂R^{b2}, NR^{c2}S(O)₂NR^{c2}R^{d2}, S(O)R^{b2}, S(O)NR^{c2}R^{d2}, S(O)₂R^{b2}, and S(O)₂NR^{c2}R^{d2}; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₃ alkylene, 4-10 membered heterocycloalkyl-C₁₋₃ alkylene, C₆₋₁₀ aryl-C₁₋₃ alkylene and 5-10 membered heteroaryl-C₁₋₃ alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

or two adjacent R² substituents on the phenyl ring, taken together with the atoms to which they are attached, form a fused 5-membered cycloalkyl ring, or a fused 5- or 6-membered heterocycloalkyl ring; wherein each fused 5- or 6-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1 or 2 ring-forming O atoms; and wherein the fused 5-membered cycloalkyl ring, and the fused 5- or 6-membered heterocycloalkyl ring are each optionally substituted with 1 or 2 substituents independently selected from R²¹;

n is selected from 0, 1, 2, and 3;

each R¹⁰ is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 4-12 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₃ alkylene, 4-12 membered heterocycloalkyl-C₁₋₃ alkylene, C₆₋₁₀ aryl-C₁₋₃ alkylene, 5-10 membered heteroaryl-C₁₋₃ alkylene, halo, D, CN, NO₂, OR^{a1}, SR^{a1}, C(O)R^{b1}, C(O)NR^{c1}R^{d1}, C(O)OR^{a1}, OC(O)R^{b1}, OC(O)NR^{c1}R^{d1}, NR^{c1}R^{d1}, NR^{c1}C(O)R^{b1}, NR^{c1}C(O)OR^{a1}, NR^{c1}C(O)NR^{c1}R^{d1}, C(=NR^{e1})R^{b1}, C(=NOR^{a1})R^{b1}, C(=NR^{e1})NR^{c1}R^{d1}, NR^{c1}C(=NR^{e1})NR^{c1}R^{d1}, NR^{c1}S(O)R^{b1}, NR^{c1}S(O)₂R^{b1}, NR^{c1}S(O)₂NR^{c1}R^{d1}, S(O)R^{b1}, S(O)NR^{c1}R^{d1}, S(O)₂R^{b1}, and S(O)₂NR^{c1}R^{d1}; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 4-12 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₃ alkylene, 4-12 membered heterocycloalkyl-C₁₋₃ alkylene, C₆₋₁₀ aryl-C₁₋₃ alkylene and 5-10 membered heteroaryl-C₁₋₃ alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹ is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₃ alkylene, 4-10 membered heterocycloalkyl-C₁₋₃ alkylene, C₆₋₁₀ aryl-C₁₋₃ alkylene, 5-10 membered heteroaryl-C₁₋₃ alkylene, halo, D, CN, OR^{a3}, SR^{a3}, C(O)R^{b3}, C(O)NR^{c3}R^{d3}, C(O)OR^{a3}, NR^{c3}R^{d3}, NR^{c3}C(O)R^{b3}, NR^{c3}C(O)OR^{a3}, NR^{c3}S(O)R^{b3}, NR^{c3}S(O)₂R^{b3}, NR^{c3}S(O)₂NR^{c3}R^{d3}, S(O)R^{b3}, S(O)NR^{c3}R^{d3}, S(O)₂R^{b3}, and S(O)₂NR^{c3}R^{d3}; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₃ alkylene, 4-10 membered heterocycloalkyl-C₁₋₃ alkylene, C₆₋₁₀ aryl-C₁₋₃ alkylene and 5-10 membered heteroaryl-C₁₋₃ alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

each R¹² is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, OR^{a5}, SR^{a5}, C(O)R^{b5}, C(O)NR^{c5}R^{d5}, C(O)OR^{a5}, NR^{c5}R^{d5}, NR^{c5}C(O)R^{b5}, NR^{c5}C(O)OR^{a5}, NR^{c5}S(O)R^{b5}, NR^{c5}S(O)₂R^{b5}, NR^{c5}S(O)₂NR^{c5}R^{d5}, S(O)R^{b5},

$S(O)NR^{c5}R^{d5}$, $S(O)_2R^{b5}$, and $S(O)_2NR^{c5}R^{d5}$; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g ;

each R^{21} is independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-3} alkylene, 4-10 membered heterocycloalkyl- C_{1-3} alkylene, C_{6-10} aryl- C_{1-3} alkylene, 5-10 membered heteroaryl- C_{1-3} alkylene, halo, D, CN, OR^{a4} , SR^{a4} , $C(O)R^{b4}$, $C(O)NR^{c4}R^{d4}$, $C(O)OR^{a4}$, $NR^{c4}R^{d4}$, $NR^{c4}C(O)R^{b4}$, $NR^{c4}C(O)OR^{a4}$, $NR^{c4}S(O)R^{b4}$, $NR^{c4}S(O)_2R^{b4}$, $NR^{c4}S(O)_2NR^{c4}R^{d4}$, $S(O)R^{b4}$, $S(O)NR^{c4}R^{d4}$, $S(O)_2R^{b4}$, and $S(O)_2NR^{c4}R^{d4}$; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-3} alkylene, 4-10 membered heterocycloalkyl- C_{1-3} alkylene, C_{6-10} aryl- C_{1-3} alkylene and 5-10 membered heteroaryl- C_{1-3} alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{22} ;

each R^{22} is independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, OR^{a6} , SR^{a6} , $C(O)R^{b6}$, $C(O)NR^{c6}R^{d6}$, $C(O)OR^{a6}$, $NR^{c6}R^{d6}$, $NR^{c6}C(O)R^{b6}$, $NR^{c6}C(O)OR^{a6}$, $NR^{c6}S(O)R^{b6}$, $NR^{c6}S(O)_2R^{b6}$, $NR^{c6}S(O)_2NR^{c6}R^{d6}$, $S(O)R^{b6}$, $S(O)NR^{c6}R^{d6}$, $S(O)_2R^{b6}$, and $S(O)_2NR^{c6}R^{d6}$; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g ;

each R^{a1} , R^{c1} and R^{d1} is independently selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl and 5-10 membered heteroaryl; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{11} ;

or any R^{c1} and R^{d1} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{11} ;

each R^{b1} is independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl and 5-10 membered heteroaryl; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 4-10

membered heterocycloalkyl, C₆₋₁₀ aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R^{e1} is independently selected from H, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylcarbonyl, C₁₋₆ alkylaminosulfonyl, carbamyl, C₁₋₆ alkylcarbamyl, di(C₁₋₆ alkyl)carbamyl, aminosulfonyl, C₁₋₆ alkylaminosulfonyl and di(C₁₋₆ alkyl)aminosulfonyl;

each R^{a2}, R^{c2} and R^{d2}, is independently selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl and 5-10 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

or any R^{c2} and R^{d2} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R²¹;

each R^{b2} is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl and 5-10 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

each R^{e2} is independently selected from H, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylcarbonyl, C₁₋₆ alkylaminosulfonyl, carbamyl, C₁₋₆ alkylcarbamyl, di(C₁₋₆ alkyl)carbamyl, aminosulfonyl, C₁₋₆ alkylaminosulfonyl and di(C₁₋₆ alkyl)aminosulfonyl;

each R^{a3}, R^{c3} and R^{d3}, is independently selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C₁₋₆ alkyl C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

or any R^{c3} and R^{d3} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R¹²;

each R^{b3} is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C₁₋₆ alkyl C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, phenyl, 5-

6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

each R^{a4}, R^{c4} and R^{d4}, is independently selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C₁₋₆ alkyl C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

or any R^{c4} and R^{d4} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R²²;

each R^{b4} is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C₁₋₆ alkyl C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

each R^{a5}, R^{c5} and R^{d5}, is independently selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl and C₁₋₆ haloalkyl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl and C₂₋₆ alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^{b5} is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl and C₁₋₆ haloalkyl; wherein said C₁₋₆ alkyl C₂₋₆ alkenyl and C₂₋₆ alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^{a6}, R^{c6} and R^{d6}, is independently selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl and C₁₋₆ haloalkyl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl and C₂₋₆ alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^{b6} is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and C₁₋₆ haloalkyl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl and C₂₋₆ alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g; and

each R^g is independently selected from OH, NO₂, CN, halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₂ alkylene, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₃ alkoxy-C₁₋₃ alkyl, C₁₋₃ alkoxy-C₁₋₃ alkoxy, HO-C₁₋₃ alkoxy, HO-C₁₋₃ alkyl, cyano-C₁₋₃ alkyl, H₂N-C₁₋₃ alkyl, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, thio, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, carbamyl, C₁₋₆ alkylcarbamyl, di(C₁₋₆ alkyl)carbamyl, carboxy, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxy carbonyl, C₁₋₆ alkylcarbonylamino, C₁₋₆ alkylsulfonylamino, aminosulfonyl, C₁₋₆ alkylaminosulfonyl, di(C₁₋₆ alkyl)aminosulfonyl,

aminosulfonylamino, C₁₋₆ alkylaminosulfonylamino, di(C₁₋₆ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₆ alkylaminocarbonylamino, and di(C₁₋₆ alkyl)aminocarbonylamino.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy¹ is selected from phenyl, pyridinyl and pyrazolyl; wherein the phenyl, pyridinyl, and pyrazolyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy¹ is selected from phenyl, pyridin-3-yl and pyrazol-4-yl; wherein the phenyl, pyridin-3-yl, and pyrazol-4-yl are each optionally substituted with 1 substituent selected from R¹⁰.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy¹ is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents selected from R¹⁰.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy¹ is selected from pyrazol-4-yl and pyridin-3-yl; wherein the pyrazol-4-yl and pyridin-3-yl are each optionally substituted with 1 or 2 substituents selected from R¹⁰.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from Cl, CH₃, OCH₃, OCD₃, OCH₂CH₃, OCHF₂, NHCH₃, CHF₂, and CH₂OH.

7. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R¹ is OCH₃.

8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein each R² is independently selected from C₁₋₆ alkyl, C₃₋₆ cycloalkyl, halo, and OR^{a2}; wherein said C₁₋₆ alkyl and C₃₋₆ cycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹.

9. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein each R² is independently selected from C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, F, Cl, CN, and OR^{a2}; wherein said C₁₋₃ alkyl, and C₃₋₆ cycloalkyl, are each optionally substituted with 1, 2 or 3 substituents independently selected from R²¹.

10. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein each R^2 is independently selected from F, methyl, CH_2CN , CD_3 , OH, OCH_3 , and cyclopropyl.

11. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein the R^2 substituents, taken together with the atoms to which they are attached, form a fused cyclopentyl group, a fused tetrahydrofuranyl group, a fused 1,4-dioxanyl group, or a fused tetrahydropyranyl group, each of which is optionally substituted with 1 or 2 substituents selected from R^{21} .

12. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein the R^2 substituents, taken together with the atoms to which they are attached, form a fused cyclopentyl group optionally substituted with 1 or 2 substituents independently selected from D, OH, CN, CH_2OH , and F.

13. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein the R^2 substituents, taken together with the atoms to which they are attached, form a fused cyclopentyl group or a fused cyclohexyl group; wherein the fused cyclopentyl group and the fused cyclohexyl group have at least one ring-forming carbon atom and each optionally have 1 or 2 ring-forming O atoms; and wherein the fused cyclopentyl group and the fused cyclohexyl group are each optionally substituted with 1 or 2 substituents independently selected from D, OH, CN, CH_2OH , and F.

14. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein the R^2 substituents, taken together with the atoms to which they are attached, form a fused cyclopentyl group.

15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein n is selected from 0 and 1.

16. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein n is 0.

17. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein each R^{10} is independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, 4-12 membered heterocycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-3} alkylene, 4-12 membered heterocycloalkyl- C_{1-3} alkylene, C_{6-10} aryl- C_{1-3} alkylene, 5-10 membered heteroaryl- C_{1-3} alkylene, halo, D, CN, OR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, and $S(O)_2R^{b1}$; wherein said C_{1-6} alkyl, C_{3-10} cycloalkyl, 4-12 membered heterocycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-3} alkylene, 4-12 membered heterocycloalkyl- C_{1-3} alkylene, C_{6-10} aryl- C_{1-3} alkylene and 5-10 membered heteroaryl- C_{1-3} alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{11} .

18. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein each R^{10} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl- C_{1-2} alkylene, 5-6 membered heteroaryl- C_{1-2} alkylene, halo, D, CN, $C(O)NR^{c1}R^{d1}$, and $NR^{c1}R^{d1}$; wherein the C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl- C_{1-2} alkylene, and 5-6 membered heteroaryl- C_{1-2} alkylene are each optionally substituted with 1 or 2 substituents independently selected from R^{11} .

19. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein each R^{10} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-10 membered heterocycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl- C_{1-2} alkylene, 5-6 membered heteroaryl- C_{1-2} alkylene, halo, D, CN, OR^{a1} , $C(O)NR^{c1}R^{d1}$, and $NR^{c1}R^{d1}$; wherein the C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-10 membered heterocycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl- C_{1-2} alkylene, and 5-6 membered heteroaryl- C_{1-2} alkylene are each optionally substituted with 1 or 2 substituents independently selected from R^{11} .

20. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein each R^{10} is independently selected from C_{1-2} alkyl, C_{1-2} haloalkyl, F, Cl, D, CN, OR^{a1} and $NR^{c1}R^{d1}$; wherein the C_{1-2} alkyl is optionally substituted with 1 or 2 substituents independently selected from R^{11} .

21. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein each R¹⁰ is independently selected from methyl, (1-methyl-1*H*-1,2,4-triazol-5-yl)methyl, pyrrolidin-3-yl, pyrrolidin-1-yl, 1-ethylpyrrolidin-3-yl, 1-methylazetidin-3-yl, 1-ethylazetidin-3-yl, 4-acetylpiperazin-1-yl, 3-cyanocyclobutyl, 1-(dimethylcarbamoyl)piperidin-4-yl, 1-(methoxycarbonyl)piperidin-4-yl, 1-(methoxycarbonyl)azetidin-3-yl, 1-acetylazetidin-3-yl, 1-(methylsulfonyl)azetidin-3-yl, 1-(dimethylcarbamoyl)azetidin-3-yl, 1-(cyclopropanecarbonyl)azetidin-3-yl, pyridin-4-ylmethyl, 2-morpholinoethyl, cyclopropyl, 2-cyanoethyl, 2-hydroxyethyl, pyridin-4-yl, 4-hydroxycyclohexyl, 4-methylpiperazin-1-yl, 4-ethylpiperazin-1-yl, morpholino, 4-methyl-3-oxopiperazin-1-yl, 4-hydroxypiperidin-1-yl, (R)-3,4-dimethylpiperazin-1-yl, (1*S*,4*S*)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl, 4-(dimethylcarbamoyl)piperidin-1-yl, 4-carboxy-4-methylpiperidin-1-yl, (1*S*,4*S*)-4-acetamidocyclohexyl, 2,4-dimethylpiperazin-1-yl, 4-(ethylcarbamoyl)piperazin-1-yl, 4-carbamoylpiperazin-1-yl, 4-isopropylpiperazin-1-yl, 4-ethylpiperazin-1-yl, 2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl, pyridin-2-ylmethyl, 1-acetylpiperidin-4-yl, 1-(methoxycarbonyl)piperidin-4-yl, (tetrahydrofuran-3-yl)oxy, 1-methyl-5-oxopyrrolidin-3-yl, 1-(2-hydroxypropanoyl)piperidin-4-yl, 1-(2-hydroxyacetyl)piperidin-4-yl, 4-carboxycyclohexyl, 3-amino-4-fluoropyrrolidin-1-yl, (7*R*,8*aS*)-7-hydroxyhexahydropyrrolo[1,2-*a*]pyrazin-2(1*H*)-yl, (7*R*,8*aS*)-7-hydroxyhexahydropyrrolo[1,2-*a*]pyrazin-2(1*H*)-yl, 4-imino-4-oxo-4λ⁶-piperazin-1-yl, (2-hydroxy-*N*-methylacetamido)pyrrolidin-1-yl, 4-(2-hydroxyethyl)piperazin-1-yl, 2-methoxyethoxy, (tetrahydro-2*H*-pyran-4-yl)oxy, cyclopropyl, and 3-(2-hydroxy-*N*-methylacetamido)azetidin-1-yl, 1-(2-hydroxyacetyl)pyrrolidin-3-yl, 1-acetylpiperidin-3-yl, 1-(3'-pyrrolidin-2'-one)pyrrolidin-3-yl, 1-(1'-methyl-(3'-pyrrolidin-2'-one))pyrrolidin-3-yl, 1-(2-propanamide)pyrrolidin-3-yl, 1-(methyl-*L*-prolyl)piperidin-4-yl, 1-(4-methylmorpholin-3-yl)pyrrolidin-3-yl, 3-cyanocyclobut-1-yl, 1-(hydroxymethylcarbamoyl)azetidin-3-yl, 1-(2-(dimethylamino)ethanecarbonyl)azetidin-3-yl, 1-(dimethylamino-methyl-acetyl)azetidin-3-yl, 1-((1-methylazetidin-2-yl)carbonyl)azetidin-3-yl, 1-(2-(4-methylpiperazin-1-yl)ethan-1-one)azetidin-3-yl, 1-(2-(4-hydroxypiperazin-1-yl)ethan-1-one)azetidin-3-yl, 1-((1-methylazetidin-2-yl)carbonyl)azetidin-3-yl, 1-(hydroxy-methyl-acetyl)azetidin-3-yl, 1-(((*trans*)-3-hydroxycyclobutylcarbonyl)azetidin-3-yl, 1-(((*cis*)-3-hydroxycyclobutylcarbonyl)azetidin-3-yl, 1-(((4-methylmorpholin-3-yl)carbonyl)azetidin-3-yl, 1-(hydroxyl-acetyl)pyrrolidin-3-yl, 1-(((tetrahydrofuran-2-yl)carbonyl)azetidin-3-yl, 1-(((tetrahydrofuran-3-yl)carbonyl)azetidin-3-yl, 1-(hydroxy-methyl-acetyl)pyrrolidin-3-yl, 1-

(3-hydroxybutanoyl)azetidin-3-yl, 1-((-3-hydroxy-3-methylcyclobutyl)carbonyl)azetidin-3-yl, 1-(4-methylmorpholin-3-yl)carbonyl)pyrrolidin-3-yl, 1-((hydroxymethyl)cyclobutylcarbonyl)azetidin-3-yl, 1-((1-ethylazetidin-2-yl)carbonyl)azetidin-3-yl, 1-((1-(2-fluoroethyl)azetidin-2-yl)carbonyl)azetidin-3-yl, 1-((1-isopropylazetidin-2-yl)carbonyl)azetidin-3-yl, 1-((1-(2-fluoroethyl)azetidin-2-yl)carbonyl)pyrrolidin-3-yl, 1-((*trans*)-3-hydroxycyclobutylcarbonyl)pyrrolidin-3-yl, 1-((*cis*)-3-hydroxycyclobutylcarbonyl)pyrrolidin-3-yl, 1-((3-hydroxy-3-methylcyclobutyl)carbonyl)pyrrolidin-3-yl, 1-(2-methoxyethan-1-one)azetidin-3-yl, 1-(2-(dimethylamino)-2-methylpropan-1-one)azetidin-3-yl, 1-((cyclopropane-1-carbonitrile)carbonyl)azetidin-3-yl, 1-((ethan-1-ol)sulfonyl)azetidin-3-yl, 1-((N,N-dimethylethan-1-amine)sulfonyl)azetidin-3-yl, 1-((2-methoxyethyl)carboxylate)azetidin-3-yl, 1-((3-methoxycyclobutyl)carbonyl)azetidin-3-yl, 3-(2-hydroxy-*N*-methylacetamide)cyclopentyl, 3-(2-hydroxypropanamid)cyclopentyl, 3-(2-hydroxyacetamide)cyclopentyl, 3-(2-hydroxyethyl)-3-azabicyclo[3.1.0]hexan-1-yl, (4-hydroxypiperidin-1-yl)methyl, (2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methyl, 1-(morpholin-4-yl)ethyl, (5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-*a*]pyrazine-7-yl)methyl, 1-(2-hydroxyethyl)piperidin-4-yl-4-carbonitrile, 1-(2-hydroxyacetyl)piperidin-4-yl-4-carbonitrile, 2-methoxyethylpiperazin-1-yl, 1-(tetrahydro-2*H*-pyran-4-carbonyl)piperidin-4-yl-4-*d*, 1-(2-methoxyacetyl)pyrrolidin-3-yl, 1-(tetrahydrofuran-2-carbonyl)pyrrolidin-3-yl, 3-(2-hydroxy-*N*-methylacetamide)azetidin-1-yl, 1-((tetrahydrofuran-2-yl)carbonyl)azetidin-3-yl, 1-((1-methylpiperidin-2-yl)carbonyl)azetidin-3-yl, 1-(2-(dimethylamino)ethan-1-one)azetidin-3-yl, 1-(3-hydroxypropan-1-one)azetidin-3-yl, 1-(2-hydroxyethan-1-one)azetidin-3-yl, 1-(2-hydroxypropan-1-one)azetidin-3-yl, 1-(2-hydroxy-*N*-methylacetamide)cyclobut-3-yl, 1-(2-hydroxyethan-1-one)-3-*d*-azetidin-3-yl, 1-carboxylatepiperidin-4-yl, 1-(morpholine-4-carbonyl)piperidin-4-yl, 1-acetylpyrrolidin-3-yl, 1-(morpholine-4-carbonyl)pyrrolidin-3-yl, cyanomethyl, 1-propanenitrile-azetidin-3-yl, 1-(2-methoxy-*N*-methylacetamide)cyclobut-3-yl, 1-(3-hydroxy-*N*-methylpropanamide)cyclobut-3-yl, 1-(2-hydroxy-*N*-methylpropanamide)cyclobut-3-yl, 1-(2-hydroxyethan-1-one)azabicyclo[3.1.0]hexan-3-yl, 1-((4-methylmorpholin-3-yl)carbonyl)azabicyclo[3.1.0]hexan-3-yl, 1-(tetrahydro-2*H*-pyran-4-yl)azabicyclo[3.1.0]hexan-3-yl, 1-(ethan-1-ol)azabicyclo[3.1.0]hexan-3-yl, 1-(4-methylmorpholine-3-carbonyl)-3-carbonitrile-pyrrolidin-3-yl, 1-(4-methylmorpholine-3-carbonyl)-4-carbonitrile-piperidin-4-yl, 1-(2-hydroxyacetyl)-3-carbonitrile-pyrrolidin-3-yl, (1,3-dimethylpiperazin-4-yl-2-one)methyl, and (2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methyl.

22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein each R^{11} is independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl, halo, D, CN, OR^{a3} , SR^{a3} , $C(O)R^{b3}$, $C(O)NR^{c3}R^{d3}$, $C(O)OR^{a3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(O)R^{b3}$, $NR^{c3}C(O)OR^{a3}$, $NR^{c3}S(O)_2R^{b3}$, $NR^{c3}S(O)_2NR^{c3}R^{d3}$, $S(O)_2R^{b3}$, and $S(O)_2NR^{c3}R^{d3}$; wherein said C_{1-6} alkyl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{12} .

23. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein each R^{11} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-4} cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, halo, D, CN, OR^{a3} , $C(O)R^{b3}$, $C(O)NR^{c3}R^{d3}$, $C(O)OR^{a3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(O)R^{b3}$, $S(O)_2R^{b3}$; and $NR^{c3}S(O)_2R^{b3}$, wherein said C_{1-3} alkyl, C_{3-4} cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl are each optionally substituted with 1 substituent selected from R^{12} .

24. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein each R^{11} is independently selected from halo, C_{1-2} alkyl, CN, OR^{a3} , $C(O)R^{b3}$, $C(O)NR^{c3}R^{d3}$, $C(O)OR^{a3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(O)R^{b3}$, $S(O)_2R^{b3}$, 1-methyl-pyrrolidin-3-yl-2-one, pyrrolidin-3-yl-2-one, 2-propanamide, $NR^{c3}S(O)_2R^{b3}$, D, and tetrahydropyran-4-yl, wherein said C_{1-2} alkyl is optionally substituted with OR^{a5} .

25. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein each R^{11} is independently selected from C_{1-3} alkyl, 4-10 membered heterocycloalkyl, F, D, CN, OR^{a3} , $C(O)R^{b3}$, $C(O)NR^{c3}R^{d3}$, $C(O)OR^{a3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(O)R^{b3}$, $NR^{c3}S(O)_2R^{b3}$, and $S(O)_2R^{b3}$; wherein said C_{1-3} alkyl, and 4-10 membered heterocycloalkyl, are each optionally substituted with 1 or 2 substituents independently selected from R^{12} .

26. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein each R^{11} is independently selected from D, methyl, ethyl, isopropyl, CN, OH, oxo, (1-methyl-1*H*-1,2,4-triazol-5-yl)methyl, CH_2CH_2OH , $C(O)CH_3$, $C(O)N(CH_3)_2$, $C(O)NH_2$, $C(O)NHCH_2CH_3$, $C(O)CH_2CH_2N(CH_3)_2$, $C(O)CH(CH_3)N(CH_3)_2$, $C(O)OCH_3$,

C(O)CH₂OH, CH(CH₃)C(O)NH₂, C(O)OH, NHC(O)CH₃, S(O)₂CH₃, cyclopropanecarbonyl, pyridin-4-yl, pyridin-2-yl, morpholino, 2-hydroxypropanoyl, 2-hydroxyacetyl, 2-hydroxyethyl, F, NH₂, N(CH₃)C(O)CH₂OH, 3'-pyrrolidin-2'-one, methyl-3'-pyrrolidin-2'-one, 1-methyl-propyl, (4-methylmorpholin-3-yl)methyl-1-one, (1-methylazetidin-2-yl)methyl-1-one, 2-(4-methylpiperazin-1-yl)ethyl-1-one, 2-(4-hydroxypiperidin-1-yl)ethyl-1-one, 2-hydroxypropyl-1-one, (trans)-3-hydroxycyclobutyl)methyl-1-one, (cis)-3-hydroxycyclobutyl)methyl-1-one, (4-methylmorpholin-3-yl)methyl-1-one, (tetrahydrofuran-2-yl)methyl-1-one, 2-hydroxypropyl-1-one, 3-hydroxybutyl-1-one, 3-hydroxy-3-methylcyclobutyl)methyl-1-one, (hydroxymethyl)cyclobutyl)methyl-one, (1-ethylazetidin-2-yl)methyl-1-one, (2-fluoroethyl)azetidin-2-yl)methyl-1-one, (1-isopropylazetidin-2-yl)methyl-1-one, 2-methoxyethyl-1-one, 2-(dimethylamino)-2-methylpropyl-1-one, (cyclopropane-1-carbonitrile)methyl-1-one, S(O)₂CH₂CH₂OH, S(O)₂CH₂CH₂N(CH₃)₂, 2-methoxyethyl-carboxyl, *N*-methylmethanesulfonamido, 2-hydroxy-*N*-methylacetamido, 2-hydroxypropanamido, tetrahydro-2*H*-pyran-4-methyl-1-one, 2-methoxyacetyl, 2-hydroxy-*N*-methylacetamido, tetrahydrofuran-2-methyl-1-one, (1-methylpiperidin-2-yl)methyl-1-one, 2-(dimethylamino)ethyl-1-one, 3-hydroxypropyl-1-one, methoxymethyl-carboxyl, morpholine-4-carbonyl, propyl nitrile, 2-methoxy-*N*-methylacetamido, 3-hydroxy-*N*-methylpropanamido, 2-hydroxy-*N*-methylpropanamido, tetrahydro-2*H*-pyran-4-yl, and 1,3-dimethylpiperazinyl-2-one.

27. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt thereof, wherein each R^{b3} is independently selected from C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, and 4-6 membered heterocycloalkyl; wherein said C₁₋₃ alkyl C₃₋₆ cycloalkyl, and 4-6 membered heterocycloalkyl, are each optionally substituted with 1 or 2 substituents independently selected from R¹².

28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein any R^{c3} and R^{d3} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5- or 6-membered heterocycloalkyl group optionally substituted with 1 or 2 substituents independently selected from R¹².

29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein each R¹² is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-7 membered heterocycloalkyl, halo, D, CN, OR^{a5}, SR^{a5}, C(O)R^{b5},

$C(O)NR^{c5}R^{d5}$, $C(O)OR^{a5}$, $NR^{c5}R^{d5}$, $NR^{c5}C(O)R^{b5}$, $S(O)_2R^{b5}$, and $S(O)_2NR^{c5}R^{d5}$; wherein said C_{1-6} alkyl, C_{3-6} cycloalkyl, and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g .

30. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein each R^{12} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-7 membered heterocycloalkyl, F, Cl, D, CN, OR^{a5} , $C(O)R^{b5}$, $C(O)NR^{c5}R^{d5}$, and $NR^{c5}R^{d5}$; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, and 4-7 membered heterocycloalkyl, are each optionally substituted with 1 substituent independently selected from R^g .

31. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein each R^{21} is independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, halo, D, CN, OR^{a4} , $C(O)R^{b4}$, $C(O)NR^{c4}R^{d4}$, $C(O)OR^{a4}$, $NR^{c4}R^{d4}$, and $S(O)_2R^{b4}$; wherein said C_{1-6} alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R^{22} .

32. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein each R^{21} is independently selected from C_{1-3} alkyl, halo, D, CN, and OR^{a4} ; wherein said C_{1-3} alkyl, is optionally substituted with 1 or 2 substituents independently selected from R^{22} .

33. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein each R^{21} is independently selected from C_{1-3} alkyl, F, Cl, D, CN, and OR^{a4} ; wherein said C_{1-3} alkyl, is optionally substituted with 1 or 2 substituents independently selected from R^{22} .


34. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein each R^{22} is independently selected from halo, D, CN, and OR^{a6} .

35. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein each R^{22} is independently selected from F, Cl, D, CN, and OR^{a6} .

36. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein R^{22} is OR^{a6} .


37. The compound of any one of claims 1-36, or a pharmaceutically acceptable salt thereof, wherein each R^g is independently selected from OH, CN, F, Cl, C_{1-3} alkyl, and C_{1-3} haloalkyl.

38. The compound of any one of claims 1-5, 8-14, and 17-37, or a pharmaceutically acceptable salt thereof, having Formula IIb:




IIb.

39. The compound of any one of claims 1, 6-14, and 17-37, or a pharmaceutically acceptable salt thereof, having Formula IIIa:




IIIa.

40. The compound of any one of claims 1, 6-14, and 17-37, or a pharmaceutically acceptable salt thereof, having Formula IIIb:




IIIb.

41. The compound of any one of claims 1, 6-14, and 17-37, or a pharmaceutically acceptable salt thereof, having Formula IIIc:




IIIc.

42. The compound of any one of claims 1-7 and 17-37, or a pharmaceutically acceptable salt thereof, having Formula IVa:



IVa.

43. The compound of any one of claims 1-7 and 17-37, or a pharmaceutically acceptable salt thereof, having Formula Va:



Va,

wherein m is 0, 1, or 2.

44. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

Cy¹ is selected from phenyl, pyridinyl and pyrazolyl; wherein the phenyl pyridinyl and pyrazolyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

R¹ is selected from Cl, C₁-₂ alkyl, C₁-₂ haloalkyl, hydroxymethyl, C₁-₂ alkoxy, C₁-₂ haloalkoxy and C₁-₂ alkylamino; wherein optionally one or more H atoms of the C₁-₂ alkyl,

C₁₋₂ haloalkyl, hydroxymethyl, C₁₋₂ alkoxy, C₁₋₂ haloalkoxy and C₁₋₂ alkylamino are replaced by one or more D atoms;

each R² and R³ are independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, halo, CN, OR^{a2}, C(O)R^{b2}, C(O)NR^{c2}R^{d2}, C(O)OR^{a2}, NR^{c2}R^{d2}, and S(O)₂R^{b2}; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl, and 4-6 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

or two adjacent R² substituents on the phenyl ring, taken together with the atoms to which they are attached, form a fused 5-membered cycloalkyl ring, or a fused 5- or 6-membered heterocycloalkyl ring; wherein each fused 5- or 6-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1 or 2 ring-forming O atoms; and wherein the fused 5- or 6-membered cycloalkyl ring, and the fused 5- or 6-membered heterocycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²¹;

n is selected from 0 and 1;

each R¹⁰ is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 4-12 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₃ alkylene, 4-12 membered heterocycloalkyl-C₁₋₃ alkylene, C₆₋₁₀ aryl-C₁₋₃ alkylene, 5-10 membered heteroaryl-C₁₋₃ alkylene, halo, D, CN, OR^{a1}, C(O)R^{b1}, C(O)NR^{c1}R^{d1}, C(O)OR^{a1}, NR^{c1}R^{d1}, NR^{c1}C(O)R^{b1}, and S(O)₂R^{b1}; wherein said C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, 4-12 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₃ alkylene, 4-12 membered heterocycloalkyl-C₁₋₃ alkylene, C₆₋₁₀ aryl-C₁₋₃ alkylene and 5-10 membered heteroaryl-C₁₋₃ alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹ is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, halo, D, CN, OR^{a3}, SR^{a3}, C(O)R^{b3}, C(O)NR^{c3}R^{d3}, C(O)OR^{a3}, NR^{c3}R^{d3}, NR^{c3}C(O)R^{b3}, NR^{c3}C(O)OR^{a3}, NR^{c3}S(O)₂R^{b3}, NR^{c3}S(O)₂NR^{c3}R^{d3}, S(O)₂R^{b3}, and S(O)₂NR^{c3}R^{d3}; wherein said C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

each R¹² is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-7 membered heterocycloalkyl, halo, D, CN, OR^{a5}, SR^{a5}, C(O)R^{b5}, C(O)NR^{c5}R^{d5}, C(O)OR^{a5}, NR^{c5}R^{d5}, NR^{c5}C(O)R^{b5}, S(O)₂R^{b5}, and S(O)₂NR^{c5}R^{d5}; wherein said C₁₋₆ alkyl, C₃₋₆ cycloalkyl,

and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R²¹ is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, D, CN, OR^{a4}, C(O)R^{b4}, C(O)NR^{c4}R^{d4}, C(O)OR^{a4}, NR^{c4}R^{d4}, and S(O)₂R^{b4}; wherein said C₁₋₆ alkyl, is optionally substituted with 1, 2, or 3 substituents independently selected from R²²;

each R²² is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, D, CN, OR^{a6}, and NR^{c6}R^{d6}; wherein said C₁₋₆ alkyl, is optionally substituted with 1 or 2 substituents independently selected from R^g;

each R^{a1}, R^{c1} and R^{d1} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, and 4-10 membered heterocycloalkyl; wherein said C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, and 4-10 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

or any R^{c1} and R^{d1} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R^{b1} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, and 4-10 membered heterocycloalkyl, wherein said C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, and 4-10 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R^{a2}, R^{c2} and R^{d2}, is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, and 4-10 membered heterocycloalkyl; wherein said C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, and 4-10 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

or any R^{c2} and R^{d2} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R²¹;

each R^{b2} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, and 4-10 membered heterocycloalkyl; wherein said C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, and 4-10 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

each R^{a3}, R^{c3} and R^{d3}, is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, and 4-7 membered heterocycloalkyl; wherein said C₁₋₆ alkyl C₃₋₆ cycloalkyl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

or any R^{c3} and R^{d3} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R¹²;

each R^{b3} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, and 4-7 membered heterocycloalkyl; wherein said C₁₋₆ alkyl C₃₋₆ cycloalkyl, and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

each R^{a4}, R^{c4} and R^{d4}, is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; wherein said C₁₋₆ alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

each R^{b4} is independently selected from C₁₋₆ alkyl, and C₁₋₆ haloalkyl; wherein said C₁₋₆ alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

each R^{a5}, R^{c5} and R^{d5}, is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; wherein said C₁₋₆ alkyl, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^{b5} is independently selected from C₁₋₆ alkyl, and C₁₋₆ haloalkyl; wherein said C₁₋₆ alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^{a6}, R^{c6} and R^{d6}, is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; wherein said C₁₋₆ alkyl, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^{b6} is independently selected from C₁₋₆ alkyl, and C₁₋₆ haloalkyl; wherein said C₁₋₆ alkyl, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g; and

each R^g is independently selected from OH, CN, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₃ alkoxy-C₁₋₃ alkyl, HO-C₁₋₃ alkyl, cyano-C₁₋₃ alkyl, H₂N-C₁₋₃ alkyl, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, carboxy, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxy carbonyl, and C₁₋₆ alkylcarbonylamino.

45. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
or a pharmaceutically acceptable salt thereof, wherein:

Cy¹ is selected from phenyl, pyridine-3-yl and pyrazol-4-yl; wherein the phenyl, pyridine-3-yl and pyrazol-4-yl of Cy¹ are each optionally substituted with 1 substituent selected from R¹⁰;

R¹ is selected from Cl, C₁₋₂ alkyl, C₁₋₂ haloalkyl, hydroxymethyl, C₁₋₂ alkoxy, C₁₋₂ haloalkoxy and C₁₋₂ alkylamino; wherein optionally one or more H atoms of the C₁₋₂ alkyl, C₁₋₂ haloalkyl, hydroxymethyl, C₁₋₂ alkoxy, C₁₋₂ haloalkoxy and C₁₋₂ alkylamino are replaced by one or more D atoms;

each R² is independently selected from C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, F, Cl, CN, and OR^{a2}; wherein said C₁₋₃ alkyl, and C₃₋₆ cycloalkyl, are each optionally substituted with 1, 2 or 3 substituents independently selected from R²¹;

or the R² substituents on the phenyl ring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered cycloalkyl ring, or a fused 5- or 6-membered heterocycloalkyl ring; wherein each fused 5- or 6-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1 or 2 ring-forming O atoms; and wherein the fused 5- or 6-membered cycloalkyl ring, and the fused 5- or 6-membered heterocycloalkyl ring are each optionally substituted with 1 or 2 substituents independently selected from R²¹;

n is 0;

each R¹⁰ is independently selected from C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, 4-10 membered heterocycloalkyl, 5-6 membered heteroaryl, 4-10 membered heterocycloalkyl-C₁₋₂ alkylene, 5-6 membered heteroaryl-C₁₋₂ alkylene, F, Cl, D, CN, OR^{a1}, C(O)NR^{c1}R^{d1}, and NR^{c1}R^{d1}; wherein said C₁₋₃ alkyl, C₃₋₆ cycloalkyl, 4-10 membered heterocycloalkyl, 5-6 membered heteroaryl, 4-10 membered heterocycloalkyl-C₁₋₂ alkylene, and 5-6 membered heteroaryl-C₁₋₂ alkylene are each optionally substituted with 1 or 2 substituents independently selected from R¹¹;

each R¹¹ is independently selected from C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, 4-10 membered heterocycloalkyl, 5-6 membered heteroaryl, F, Cl, D, CN, OR^{a3}, C(O)R^{b3}, C(O)NR^{c3}R^{d3}, C(O)OR^{a3}, NR^{c3}R^{d3}, NR^{c3}C(O)R^{b3}, NR^{c3}S(O)₂R^{b3}, S(O)₂R^{b3}, and S(O)₂NR^{c3}R^{d3}; wherein said C₁₋₃ alkyl, C₃₋₆ cycloalkyl, 4-10 membered heterocycloalkyl, and 5-6 membered heteroaryl, are each optionally substituted with 1 or 2 substituents independently selected from R¹²;

each R¹² is independently selected from C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, 4-7 membered heterocycloalkyl, F, Cl, D, CN, OR^{a5}, C(O)R^{b5}, C(O)NR^{c5}R^{d5}, and NR^{c5}R^{d5}; wherein said C₁₋₃ alkyl, C₃₋₆ cycloalkyl, and 4-7 membered heterocycloalkyl, are each optionally substituted with 1 substituent independently selected from R^g;

R^{21} is independently selected from C_{1-3} alkyl, F, Cl, D, CN, and OR^{a4} ; wherein said C_{1-3} alkyl, is optionally substituted with 1 or 2 substituents independently selected from R^{22} ; each R^{22} is independently selected from F, Cl, D, CN, and OR^{a6} ; each R^{a1} , R^{c1} and R^{d1} is independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, and 4-6 membered heterocycloalkyl; wherein said C_{1-3} alkyl, and 4-6 membered heterocycloalkyl, are each optionally substituted with 1 substituent independently selected from R^{11} ; each R^{a2} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl; each R^{a3} , R^{c3} and R^{d3} , is independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, and 4-6 membered heterocycloalkyl; wherein said C_{1-3} alkyl C_{3-6} cycloalkyl, and 4-6 membered heterocycloalkyl are each optionally substituted with 1 or 2 substituents independently selected from R^{12} ; or any R^{c3} and R^{d3} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5- or 6-membered heterocycloalkyl group optionally substituted with 1 or 2 substituents independently selected from R^{12} ; each R^{b3} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, and 4-6 membered heterocycloalkyl; wherein said C_{1-3} alkyl C_{3-6} cycloalkyl, and 4-6 membered heterocycloalkyl, are each optionally substituted with 1 or 2 substituents independently selected from R^{12} ; each R^{a4} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl; each R^{a5} , R^{c5} and R^{d5} , is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl; wherein said C_{1-3} alkyl, is optionally substituted with 1 substituent independently selected from R^g ; each R^{b5} is independently selected from C_{1-3} alkyl, and C_{1-3} haloalkyl; wherein said C_{1-3} alkyl is optionally substituted with 1 substituents independently selected from R^g ; each R^{a6} is independently selected from H, and C_{1-3} alkyl; and each R^g is independently selected from OH, CN, F, Cl, C_{1-3} alkyl, and C_{1-3} haloalkyl.

46. The compound of claim 1, selected from:

5-(2,3-dimethylphenyl)-6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

5-(2,3-dimethylphenyl)-6-methoxy-3-(1-((1-methyl-1*H*-1,2,4-triazol-5-yl)methyl)-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

5-(2,3-dihydrobenzofuran-7-yl)-6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

2-(3-(6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2-methylphenyl)acetonitrile;

1-(4-(5-(6-(difluoromethoxy)-5-(2,3-dimethylphenyl)-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperazin-1-yl)ethan-1-one;

4-(6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-inden-1-ol;

4-(6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

4-(6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-inden-2-ol;

(4-(6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-inden-1-yl)methanol;

2-fluoro-4-(6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-inden-1-ol;

5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-3-(1-(pyrrolidin-3-yl)-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

5-(2,3-dihydro-1*H*-inden-4-yl)-3-(1-(1-ethylpyrrolidin-3-yl)-1*H*-pyrazol-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridine;

3-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)cyclobutanecarbonitrile;

5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-3-(1-(1-methylazetidin-3-yl)-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

5-(2,3-dihydro-1*H*-inden-4-yl)-3-(1-(1-ethylazetidin-3-yl)-1*H*-pyrazol-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridine;

4-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)-*N,N*-dimethylpiperidine-1-carboxamide;

methyl 4-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;

methyl 3-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidine-1-carboxylate;

1-(3-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)ethan-1-one;

5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-3-(1-(1-(methylsulfonyl)azetidin-3-yl)-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

3-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)-*N,N*-dimethylazetidine-1-carboxamide;

cyclopropyl(3-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)methanone;

5-(2,3-dihydro-1*H*-inden-4-yl)-6-ethoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-3-(1-(pyridin-4-ylmethyl)-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

4-(2-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)ethyl)morpholine;

3-(1-cyclopropyl-1*H*-pyrazol-4-yl)-5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridine;

3-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)propanenitrile;

2-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)ethan-1-ol;

5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-3-(1-(pyridin-4-yl)-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

(*trans*)-4-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)cyclohexan-1-ol;

5-(2,3-dimethylphenyl)-*N*-methyl-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-6-amine;

6-(difluoromethyl)-5-(2,3-dihydro-1*H*-inden-4-yl)-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

(5-(2,3-dihydro-1*H*-inden-4-yl)-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-6-yl)methanol;

5-(2,3-dihydro-1*H*-inden-4-yl)-*N*-methyl-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-6-amine;

(5-(2,3-dimethylphenyl)-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-6-yl)methanol;

4-(6-chloro-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-inden-2-ol;

5-(2,3-dimethylphenyl)-6-methyl-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

5-(2,3-dimethylphenyl)-6-methoxy-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

5-(2,3-dimethylphenyl)-3-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridine;

1-(4-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperazin-1-yl)ethan-1-one;

4-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)morpholine;

4-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-1-methylpiperazin-2-one;

1-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperidin-4-ol;

(*R*)-5-(2,3-dimethylphenyl)-3-(6-(3,4-dimethylpiperazin-1-yl)pyridin-3-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridine;

5-(2,3-dimethylphenyl)-6-(methoxy-*d*3)-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

5-(2,3-dimethylphenyl)-6-methoxy-3-(6-((1*S*,4*S*)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

1-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-*N,N*-dimethylpiperidine-4-carboxamide;

1-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-4-methylpiperidine-4-carboxylic acid;

3-(4-(5-(2-fluoro-3-methylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)-*N,N*-dimethylazetidine-1-carboxamide;

N-((*cis*)-4-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)cyclohexyl)acetamide;

5-(2,3-dihydro-1*H*-inden-4-yl)-3-(6-(2,4-dimethylpiperazin-1-yl)pyridin-3-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridine;

2-(3-(3-(6-(4-acetyl piperazin-1-yl)pyridin-3-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2-methylphenyl)acetonitrile;

2-(3-(6-methoxy-3-(6-morpholinopyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2-methylphenyl)acetonitrile;

5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-3-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

4-(5-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)morpholine;

4-(5-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-*N*-ethylpiperazine-1-carboxamide;

4-(5-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperazine-1-carboxamide;

1-(4-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)phenyl)piperazin-1-yl)ethan-1-one;

5-(2,3-dihydro-1*H*-inden-4-yl)-3-(4-(4-isopropylpiperazin-1-yl)phenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridine;

5-(2,3-dihydro-1*H*-inden-4-yl)-3-(4-(4-ethylpiperazin-1-yl)phenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridine;

1-(4-(5-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperazin-1-yl)ethan-1-one;

8-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;

5-(2,3-dimethylphenyl)-6-methoxy-3-(1-(pyridin-2-ylmethyl)-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

3-(1-cyclopropyl-1*H*-pyrazol-4-yl)-5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridine;

6-methoxy-5-(2-methyl-3-(methyl-*d*3)phenyl)-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

1-(4-(4-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)ethan-1-one;

methyl 4-(4-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;

methyl 3-(4-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidine-1-carboxylate; and

3-(4-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)-*N,N*-dimethylazetidine-1-carboxamide;

or a pharmaceutically acceptable salt of any of the aforementioned.

47. The compound of claim 1, selected from:

2-fluoro-4-(6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-inden-1-ol;

5-(2,3-dimethylphenyl)-6-methoxy-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

4-(6-methoxy-3-(6-((tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-inden-2-ol;

4-(6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl) 2,3-dihydro-1*H*-inden-2-ol;

4-(6-methoxy-3-(6-(1-methyl-5-oxopyrrolidin-3-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

(*S*)-1-(4-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperidin-1-yl)-2-hydroxypropan-1-one;

1-(4-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperidin-1-yl)-2-hydroxyethan-1-one;

4-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)cyclohexane-1-carboxylic acid;

(3*S*,4*R*)-1-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-4-fluoropyrrolidin-3-amine;

(2*S*)-1-(4-(5-(5-(2-fluoro-2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperidin-1-yl)-2-hydroxypropan-1-one;

1-(4-(5-(5-(2-fluoro-2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperidin-1-yl)-2-hydroxyethan-1-one;

(7*R*,8*aS*)-2-(5-(5-(2-fluoro-2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-*a*]pyrazin-7-ol;

5-(2-fluoro-2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-3-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

(7*S*,8*aR*)-2-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-*a*]pyrazin-7-ol;

4-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-1-imino-1λ⁶-thiomorpholine 1-oxide;

(7*R*,8*aS*)-2-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-*a*]pyrazin-7-ol;

(S)-*N*-(1-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)-2-hydroxy-*N*-methylacetamide;
 2-(3-(3-(6-(4-(2-hydroxyethyl)piperazin-1-yl)pyridin-3-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2-methylphenyl)acetonitrile;
(7R,8aS)-2-(5-(6-methoxy-5-(3-methoxy-2-methylphenyl)-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-*a*]pyrazin-7-ol;
(7R,8aS)-2-(5-(5-(2,3-dihydrobenzo[*b*][1,4]dioxin-5-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-*a*]pyrazin-7-ol;
(7R,8aS)-2-(5-(5-(chroman-5-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-*a*]pyrazin-7-ol;
(7R,8aS)-2-(5-(5-(2-fluoro-3-methylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-*a*]pyrazin-7-ol;
 4-(6-methoxy-3-(6-(2-methoxyethoxy)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-inden-2-ol;
 4-(6-methoxy-3-(6-((tetrahydro-2*H*-pyran-4-yl)oxy)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-inden-2-ol;
 4-(3-(6-cyclopropylpyridin-3-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-inden-2-ol; and
N-(1-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)azetidin-3-yl)-2-hydroxy-*N*-methylacetamide;
 or a pharmaceutically acceptable salt of any of the aforementioned.

48. The compound of claim 1, selected from:

1-(4-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperidin-1-yl)ethan-1-one;
 1-(4-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperidin-1-yl)-2-hydroxyethan-1-one;
 1-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)pyrrolidin-1-yl)-2-hydroxyethan-1-one (Peak 1);
 1-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)pyrrolidin-1-yl)-2-hydroxyethan-1-one (Peak 2);
 1-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)pyrrolidin-1-yl)ethan-1-one (Peak 1);

1-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)pyrrolidin-1-yl)ethan-1-one (Peak 2);

3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-[1,3'-bipyrrolidin]-2'-one (Peak 1);

3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-1'-methyl-[1,3'-bipyrrolidin]-2'-one (Peak 1);

2-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)pyrrolidin-1-yl)propanamide (Peak 1);

5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-3-(6-(1-(methyl-*L*-prolyl)piperidin-4-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridine;

(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)pyrrolidin-1-yl)((*R*)-4-methylmorpholin-3-yl)methanone (Peak 2);

4-(6-Methoxy-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

4-(3-(1-(3-Cyanocyclobutyl)-1*H*-pyrazol-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

4-(3-(1-(1-Acetylpiperidin-4-yl)-1*H*-pyrazol-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

4-(3-(6-(4-Hydroxycyclohexyl)pyridin-3-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

4-(3-(6-(4-(2-Hydroxyethyl)piperazin-1-yl)pyridin-3-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

4-(3-(6-(1-(2-Hydroxyacetyl)piperidin-4-yl)pyridin-3-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)-2-hydroxyethan-1-one;

1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)-3-(dimethylamino)propan-1-one;

(*S*)-1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)-2-(dimethylamino)propan-1-one;

(*S*)-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)(1-methylazetidin-2-yl)methanone;

1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)-2-(4-methylpiperazin-1-yl)ethan-1-one;

1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)-2-(4-hydroxypiperidin-1-yl)ethan-1-one;

(*R*)-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)(1-methylazetidin-2-yl)methanone;

(*R*)-1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)-2-hydroxypropan-1-one;

(*S*)-1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)-2-hydroxypropan-1-one;

(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)((*trans*)-3-hydroxycyclobutyl)methanone;

(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)((*cis*)-3-hydroxycyclobutyl)methanone;

(*R*)-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)(4-methylmorpholin-3-yl)methanone;

(*S*)-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)(4-methylmorpholin-3-yl)methanone;

(*S*)-1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)pyrrolidin-1-yl)-2-hydroxyethan-1-one;

(*S*)-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)(tetrahydrofuran-2-yl)methanone;

(*S*)-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)(tetrahydrofuran-3-yl)methanone;

(*R*)-1-((*S*)-3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)pyrrolidin-1-yl)-2-hydroxypropan-1-one;

(*S*)-1-((*S*)-3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)pyrrolidin-1-yl)-2-hydroxypropan-1-one;

(*R*)-1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)-3-hydroxybutan-1-one;

(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)((1*r*,3*r*)-3-hydroxy-3-methylcyclobutyl)methanone;

(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)((1*s*,3*s*)-3-hydroxy-3-methylcyclobutyl)methanone;

((*R*)-3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)pyrrolidin-1-yl)((*S*)-4-methylmorpholin-3-yl)methanone;

((*S*)-3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)pyrrolidin-1-yl)((*R*)-4-methylmorpholin-3-yl)methanone;
 (3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)(1-(hydroxymethyl)cyclobutyl)methanone;
 (*S*)-(3-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)(1-ethylazetidin-2-yl)methanone;
 (*S*)-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)(1-(2-fluoroethyl)azetidin-2-yl)methanone;
 (*S*)-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)(1-isopropylazetidin-2-yl)methanone;
 ((*S*)-3-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)pyrrolidin-1-yl)((*S*)-1-(2-fluoroethyl)azetidin-2-yl)methanone;
 ((*S*)-3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)pyrrolidin-1-yl)((*trans*)-3-hydroxycyclobutyl)methanone;
 ((*S*)-3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)pyrrolidin-1-yl)((*cis*)-3-hydroxycyclobutyl)methanone;
 ((*S*)-3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)pyrrolidin-1-yl)((1*s*,3*r*)-3-hydroxy-3-methylcyclobutyl)methanone;
 1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)-2-methoxyethan-1-one;
 1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)-2-(dimethylamino)-2-methylpropan-1-one;
 1-(3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidine-1-carbonyl)cyclopropane-1-carbonitrile;
 2-((3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)sulfonyl)ethan-1-ol;
 2-((3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)sulfonyl)-*N,N*-dimethylethan-1-amine;
 2-Methoxyethyl 3-(4-(5-(2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidine-1-carboxylate;
 (3-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)azetidin-1-yl)((1*s*,3*s*)-3-methoxycyclobutyl)methanone;
N-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)cyclopentyl)-*N*-methylmethanesulfonamide;

N-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)cyclopentyl)-2-hydroxy-*N*-methylacetamide (Peak 1);

(2*S*)-*N*-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)cyclopentyl)-2-hydroxypropanamid;

N-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)cyclopentyl)-2-hydroxyacetamide;

2-(1-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)phenyl)-3-azabicyclo[3.1.0]hexan-3-yl)ethan-1-ol;

4-(3-(4-((1*R*,5*S*)-3-(2-Hydroxyethyl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

1-((5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)methyl)piperidin-4-ol;

5-((5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)methyl)-2-oxa-5-azabicyclo[2.2.1]heptane;

4-(1-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)ethyl)morpholine;

7-((5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)methyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-*a*]pyrazine;

4-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-1-(2-hydroxyethyl)piperidine-4-carbonitrile;

4-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-1-(2-hydroxyacetyl)piperidine-4-carbonitrile;

2-(3-(6-Methoxy-3-(6-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2-methylphenyl)acetonitrile;

4-(6-Methoxy-3-(1-(1-(tetrahydro-2*H*-pyran-4-carbonyl)piperidin-4-yl-4-*d*)-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

4-(6-Methoxy-3-(1-((*S*)-1-(2-methoxyacetyl)pyrrolidin-3-yl)-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

4-(6-Methoxy-3-(1-((*S*)-1-((*S*)-tetrahydrofuran-2-carbonyl)pyrrolidin-3-yl)-1*H*-pyrazol-4-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

(7*R*,8*aS*)-2-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-*a*]pyrazin-7-ol;

N-(1-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)azetidin-3-yl)-2-hydroxy-*N*-methylacetamide;

(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)azetidin-1-yl)(tetrahydrofuran-2-yl)methanone;

(*S*)-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)azetidin-1-yl)(1-methylpiperidin-2-yl)methanone;

1-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)azetidin-1-yl)-2-(dimethylamino)ethan-1-one;

1-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)azetidin-1-yl)-3-hydroxypropan-1-one;

1-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)azetidin-1-yl)-2-hydroxyethan-1-one;

(*S*)-1-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)azetidin-1-yl)-2-hydroxypropan-1-one;

N-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)cyclobutyl)-2-hydroxy-*N*-methylacetamide;

1-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)azetidin-1-yl-3-d)-2-hydroxyethan-1-one;

Methyl 4-(5-(5-(1-Cyano-2,3-dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)piperidine-1-carboxylate;

4-(6-Methoxy-3-(6-(1-(morpholine-4-carbonyl)piperidin-4-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile, Peak 2;

4-(3-(6-(1-Acetyl)piperidin-4-yl)pyridin-3-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile, Peak 2;

4-(3-(6-(1-Acetylpyrrolidin-3-yl)pyridin-3-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

4-(6-Methoxy-3-(6-(1-(morpholine-4-carbonyl)pyrrolidin-3-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

4-(3-(1-(Cyanomethyl)-1*H*-pyrazol-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

4-(6-Methoxy-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-5-yl)-2,3-dihydro-1*H*-indene-1-carbonitrile;

3-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)azetidin-1-yl)propanenitrile;

N-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)cyclobutyl)-2-methoxy-*N*-methylacetamide;

N-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)cyclobutyl)-3-hydroxy-*N*-methylpropanamide;

(*S*)-*N*-(3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)cyclobutyl)-2-hydroxy-*N*-methylpropanamide;

1-(1-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-hydroxyethan-1-one;

(*R*)-1-(1-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-hydroxyethan-1-one, two enantiomers;

(*S*)-1-(1-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-hydroxyethan-1-one, two enantiomers;

(1-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-3-yl)((*R*)-4-methylmorpholin-3-yl)methanone;

5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-3-(6-(3-(tetrahydro-2*H*-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)pyridin-3-yl)-1*H*-pyrazolo[4,3-*b*]pyridine

2-(1-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-3-yl)ethan-1-ol;

(*R*)-2-(1-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-3-yl)ethan-1-ol, two enantiomers;

(*S*)-2-(1-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-3-yl)ethan-1-ol, two enantiomers;

3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-1-((*R*)-4-methylmorpholine-3-carbonyl)pyrrolidine-3-carbonitrile;

(*R*)-4-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-1-(4-methylmorpholine-3-carbonyl)piperidine-4-carbonitrile;

1-(1-(4-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)-1*H*-pyrazol-1-yl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-hydroxyethan-1-one;

3-(5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)-1-(2-hydroxyacetyl)pyrrolidine-3-carbonitrile;

(*S*)-4-((5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)methyl)-1,3-dimethylpiperazin-2-one; and

(1*R*,4*R*)-5-((5-(5-(2,3-Dihydro-1*H*-inden-4-yl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)methyl)-2-oxa-5-azabicyclo[2.2.1]heptane;

or a pharmaceutically acceptable salt of any of the aforementioned.

49. The compound of claim 1, wherein the compound is (7*R*,8*aS*)-2-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-*a*]pyrazin-7-ol, or a pharmaceutically acceptable salt thereof.
50. The compound of claim 1, wherein the compound is (7*R*,8*aS*)-2-(5-(5-(2,3-dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-*a*]pyrazin-7-ol.
51. A pharmaceutical composition comprising a compound of any one of claims 1-50 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
52. A method of inhibiting an FGFR3 enzyme comprising contacting said enzyme *in vitro* with a compound of any one of claims 1-50 or a pharmaceutically acceptable salt thereof, or a composition of claim 51.
53. Use of a compound of any one of claims 1-50 or a pharmaceutically acceptable salt thereof, or a composition of claim 51, in the manufacture of a medicament for the treatment of cancer.
54. Use of a compound of any one of claims 1-50 or a pharmaceutically acceptable salt thereof, or a composition of claim 51, in the manufacture of a medicament for the treatment of cancer in combination with another therapy or therapeutic agent.
55. The use of claim 53 or 54, wherein said cancer is selected from adenocarcinoma, bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, colorectal cancer, endometrial cancer, esophageal cancer, gall bladder cancer, gastric cancer, glioma, head and neck cancer, hepatocellular cancer, kidney cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin cancer, thyroid cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglobulinemia, hairy cell lymphoma, and Burkett's lymphoma.
56. The use of claim 53 or 54, wherein said cancer is selected from adenocarcinoma, bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, endometrial cancer,

gastric cancer, glioma, head and neck cancer, lung cancer, ovarian cancer, leukemia, and multiple myeloma.

57. Use of a compound of any one of claims 1-50 or a pharmaceutically acceptable salt thereof, or a composition of claim 51, in the manufacture of a medicament for the treatment of a skeletal or chondrocyte disorder.

58. The use of claim 57, wherein said skeletal or chondrocyte disorder is selected from achondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndrome.